Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

Rhea-AI Summary

Royalty Pharma (Nasdaq: RPRX) has scheduled its fourth quarter and full year 2024 financial results announcement for Tuesday, February 11, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day. Investors can access the conference call details and live webcast through the company's website investor relations section. A replay of both the call and webcast will remain available on the website for a minimum of 30 days.

News Market Reaction – RPRX

+0.03%

1 alert

+0.03% News Effect

On the day this news was published, RPRX gained 0.03%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day.

Conference Call Information

Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6637
ir@royaltypharma.com

FAQ

When will Royalty Pharma (RPRX) release Q4 2024 earnings?

Royalty Pharma will release its Q4 and full year 2024 earnings on Tuesday, February 11, 2025, before U.S. markets open.

What time is Royalty Pharma's (RPRX) Q4 2024 earnings call?

Royalty Pharma's Q4 2024 earnings conference call is scheduled for 8:30 a.m. Eastern Time on February 11, 2025.

How can investors access Royalty Pharma's (RPRX) Q4 2024 earnings call?

Investors can access the conference call and webcast through Royalty Pharma's website at the 'Investors' page.

How long will Royalty Pharma's (RPRX) Q4 2024 earnings call replay be available?

The replay of the conference call and webcast will be archived on Royalty Pharma's website for at least 30 days.